Astex gets orphan drug designation; Seattle Genetics, Agensys expand collaboration;

> Seattle Genetics and Agensys, an affiliate of Astellas, have expanded the companies' antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of IND submission. Release

> Astex Therapeutics has been granted orphan-drug designation by the U.S. Food and Drug Administration for AT9283, its combinatorial oncogenic kinase inhibitor, for the treatment of patients with Acute Myeloid Leukaemia (AML). Release

> Handok Pharmaceuticals will develop and commercialize Spectrum Pharmaceuticals's experimental cancer drug in South Korea as part of a deal valued at more than $19 million. Report

Pharma News

> In an interview with the Financial Times, Sanofi CEO Chris Viehbacher bucks conventional pharma wisdom. Report

> A Philadelphia jury ordered Pfizer to pay $6.3 million in compensatory damages to an Illinois woman who alleged that the menopause treatments Premarin, Provera and Prempro caused her breast cancer. Article

> A Biogen Idec shareholder is castigating CEO James Mullen (photo) for selling $85 million in company stock and picking up $63 million in compensation, Reuters reports. And no, the shareholder isn't Carl Icahn. Report

> FDA is sifting through some preliminary data suggesting that Abbott Laboratories' obesity drug Meridia (sibutramine) may carry cardiovascular risks. Report


Biotech IT News

> As Amazon continues to distance itself from the public-cloud computing provider pack, private clouds remain a not-ready-for-prime-time alternative. So says Chris Dagdigian of high-performance computing consultancy BioTeam. Report

> Clinical informatics meets patient data in a solution that targets the lagging subject enrollment of clinical trials. The software capitalizes on the ability of top-ranking investigators to enroll patients more quickly than most others, and it taps into database of prospective trial subjects. Report

> Rival drug developers may become allies in an MIT project called New Drug Development Paradigms. Among the project aims: New prediction models and more open sharing of information about the biology of diseases. Report

> Taking the open concept a step further is the Bioinformatics Organization, an open source practitioner that uses wiki software to let researchers post their models, questions, experiments and discoveries. Report

> As Google has become a tool for flu-tracking, so the mobile phone will be making medical diagnoses. Thanks to a Gates Foundation grant, STAR Analytical Services is developing software to analyze the sound of a cough. Report

And Finally... Scientists at the University of Bonn have discovered a previously unknown fruit fly gene that controls the metabolism of fat. Larvae in which this gene is defective lose their entire fat reserves. Mammals carry a group of genes that are very similar, which could lead to new medicines to fight obesity. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.